Jeevan Bio Sciences, Inc. (JBI) is an Atlanta based biotechnology company committed to the development of cancer drug development platform using genetically diverse 3D cancer stem cell models (in vitro), xeno-free reagents, and proprietary biomarkers to support the development of next-generation genetically specific cancer drug therapies. By creating a proprietary in-vitro cellular model system, JBI intends to bridge the gap between research, medicine, and the quality of life for genetically diverse patient populations who would benefit the most from “personalized” cancer treatment therapies. Our team has a combined 25 years of technology commercialization experience, over 60 years of stem cell R&D expertise, as well as over 100 years of cellular biological experience.